March 5-8, 2026
J.W. Marriott Los Angeles L.A. Live
Los Angeles, California

Cochairs

Andrew J. Aguirre, Dana-Farber Cancer Institute, Boston, Massachusetts
Channing J. Der, University of North Carolina, Chapel Hill, North Carolina
David S. Hong, The University of Texas MD Anderson Cancer Center, Houston, Texas
Kevan M. Shokat, University of California, San Francisco, California

RAS mutations are found in about one-third of human cancers and remain a major focus of cancer research and therapy development. This meeting will highlight progress in understanding RAS biology—from biochemistry, structure, and effector signaling to new strategies that target RAS-driven cancers. Sessions will explore why colorectal cancers are less responsive to RAS inhibitors, the promise of combination approaches, and emerging resistance and immunobiology research.

Bringing together leading researchers and clinicians from academia, industry, biotech, government, non-profits, and foundations, this conference will feature clinical trial updates on next-generation inhibitors and advances in genomics and liquid biopsy technologies for early detection and monitoring of RAS-driven cancers. Together, these discussions will define the current state and future directions of RAS cancer research, bridging discovery to patient impact.

Please Note: All presentations at this event represent the opinions of the presenter and do not represent the position or the opinion of the AACR or its members.

#AACRras26